Arbutus Biopharma Announces Presentation Of Imdusiran Data At EASL Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma announced the presentation of data on its drug imdusiran at the EASL Congress 2024. Key findings include a significant percentage of subjects achieving HBsAg ≤ LLOQ with detectable anti-HBs after receiving 4 or 6 doses of imdusiran plus 24 weeks of IFN. The study is ongoing, with more data to be presented.
May 22, 2024 | 6:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arbutus Biopharma's presentation of imdusiran data at EASL Congress 2024 shows promising results, with 28% of subjects achieving HBsAg ≤ LLOQ with detectable anti-HBs. The ongoing study and upcoming data presentation could positively impact the stock.
The presentation of promising data on imdusiran, showing significant results in 28% of subjects, is likely to positively impact Arbutus Biopharma's stock. The ongoing nature of the study and the anticipation of additional data further support a positive short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100